Abstract
Midostaurin (Rydapt(A (R))) is a multikinase inhibitor being developed by Novartis Pharmaceuticals. In April 2017, midostaurin was approved in the USA......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
